E. MANTIA

Scopo dello studio: valutare la durability, la safety e il recupero immunologico in una coorte di pazienti (pz) HIV positivi (+) in terapia con Maraviroc (MVC) Metodi: Sono stati analizzati i dati di pz HIV + in terapia antiretrovirale (ART) contenente MVC almeno da 6 mesi (tutti con virus CCR-5 tropico secondo l'analisi genotipica e...

INTRODUCTION: The persistence of immune activation and inflammation in HIV patients with HIV-RNA (VL) undetectable causes many co-morbidities [1-3]. The aim of this study is to correlate monocytes (m) and NK cell activation levels, soluble markers and oxidative stress with clinical, biochemical and metabolic data in HIV-1 infected patients...

Purpose of the study: Promising research suggest that maraviroc (MVC) has favourable clinical outcome in HIV-infected patients (pts). Aim of the study is to assess: durability, safety profile and immunovirological recovery in a large MVC-based cohort. Methods: All HIV pts treated with antiretroviral therapy (ART) containing MVC for at least 6...